Publications by authors named "Morgan DeCarli"

Background: Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses. We aimed to evaluate BAT in patients with metastatic castration-resistant prostate cancer that progressed after enzalutamide.

Methods: We did this single-centre, open-label, phase 2, multicohort study in the USA.

View Article and Find Full Text PDF